{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T20:48:17Z","timestamp":1770670097575,"version":"3.49.0"},"reference-count":19,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100014468","name":"Mallinckrodt Pharmaceuticals","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014468","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Respir Dis"],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p> Repository corticotropin injection (RCI) has regulatory approval for many indications, including symptomatic sarcoidosis. This large case series of patients with advanced symptomatic sarcoidosis treated with RCI describes patient characteristics, RCI utilization patterns, concomitant therapies, and physicians\u2019 assessments of treatment response. <\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p> Patients \u2a7e18\u2009years with symptomatic sarcoidosis, treated with RCI in the previous 36\u2009months, who had completed a course of RCI or received RCI for \u2a7e6\u2009months at the time of data collection were included. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p> The study included 302 patients (mean age, 51\u2009years; 52%, women) with a mean 4.8 years since initial diagnosis of sarcoidosis. Most patients (76%) had extrapulmonary involvement, primarily in the skin (28%), joints (25%), heart (22%), and eyes (22%); 34% had multiple (\u2a7e2) organ involvement. The mean duration of RCI treatment was 32.5\u2009weeks, with 61.6% of patients continuing RCI therapy for \u2a7e6\u2009months. The RCI utilization pattern indicated an individualized approach to therapy, with a higher starting dose associated with a shorter duration of therapy compared with a lower starting dose. The percentage of patients who used corticosteroids decreased from 61.3% during the 3\u2009months before initiation of RCI to 12.9% 3\u2009months after RCI therapy; the mean daily dose of corticosteroid decreased from 18.2\u2009mg to 9.9\u2009mg. The proportion of patients given &lt;10\u2009mg\/day of prednisone increased from 21% before RCI use to 47% 3\u2009months after RCI use. According to physicians\u2019 assessments of change in patients\u2019 health status after RCI therapy, overall status improved in 95% of patients, overall symptoms in 73%, lung function in 38%, and inflammation in 33%. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p> The findings suggest that RCI is a viable treatment option for patients with advanced symptomatic sarcoidosis and provide insights on patient characteristics and practice patterns to help clinicians determine appropriate use. The reviews of this paper are available via the supplemental material section. <\/jats:p><\/jats:sec>","DOI":"10.1177\/1753466619888127","type":"journal-article","created":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T08:39:12Z","timestamp":1573720752000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":28,"title":["Repository corticotropin injection in patients with advanced symptomatic sarcoidosis: retrospective analysis of medical records"],"prefix":"10.1177","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9921-1726","authenticated-orcid":false,"given":"Ishveen","family":"Chopra","sequence":"first","affiliation":[{"name":"Manticore Consultancy, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yimin","family":"Qin","sequence":"additional","affiliation":[{"name":"Mallinckrodt Pharmaceuticals, Bedminster, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Kranyak","sequence":"additional","affiliation":[{"name":"Mallinckrodt Pharmaceuticals, Bedminster, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack R.","family":"Gallagher","sequence":"additional","affiliation":[{"name":"Clarity Pharma Research LLC, Spartanburg, SC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kylee","family":"Heap","sequence":"additional","affiliation":[{"name":"Clarity Pharma Research LLC, Spartanburg, SC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Carroll","sequence":"additional","affiliation":[{"name":"Clarity Pharma Research LLC, Spartanburg, SC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George J.","family":"Wan","sequence":"additional","affiliation":[{"name":"Mallinckrodt Pharmaceuticals, 1425 U.S. Route 206, Bedminster, NJ 07921, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2019,11,14]]},"reference":[{"key":"bibr1-1753466619888127","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1164\/ajrccm.160.2.ats4-99","volume":"160","author":"Statement on sarcoidosis","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"bibr2-1753466619888127","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60680-7"},{"key":"bibr3-1753466619888127","first-page":"840","volume":"93","author":"Soto-Gomez N","year":"2016","journal-title":"Am Fam Physician"},{"key":"bibr4-1753466619888127","first-page":"312","volume":"70","author":"Wu JJ","year":"2004","journal-title":"Am Fam Physician"},{"key":"bibr5-1753466619888127","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra071714"},{"key":"bibr6-1753466619888127","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201511-760OC"},{"key":"bibr7-1753466619888127","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.007844"},{"key":"bibr8-1753466619888127","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0000000000000080"},{"key":"bibr9-1753466619888127","unstructured":"FSR. Sarcoidosis treatment guidelines, https:\/\/www.stopsarcoidosis.org\/wp-content\/uploads\/FSR-Physicians-Protocol1.pdf (2017, accessed 23 June 2019)."},{"key":"bibr10-1753466619888127","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2018.1474090"},{"key":"bibr11-1753466619888127","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2018.1474750"},{"key":"bibr12-1753466619888127","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S176026"},{"key":"bibr13-1753466619888127","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(15)00199-X"},{"key":"bibr14-1753466619888127","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2013.00021"},{"key":"bibr15-1753466619888127","unstructured":"Acthar Gel (repository corticotropin injection) [prescribing information]. Bedminster, NJ: Mallinckrodt ARD LLC, 2019."},{"key":"bibr16-1753466619888127","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2015.02.003"},{"key":"bibr17-1753466619888127","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2015.11.007"},{"key":"bibr18-1753466619888127","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-017-9994-4"},{"key":"bibr19-1753466619888127","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.164.10.2104046"}],"container-title":["Therapeutic Advances in Respiratory Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1753466619888127","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1753466619888127","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1753466619888127","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T06:47:43Z","timestamp":1741070863000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1753466619888127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":19,"alternative-id":["10.1177\/1753466619888127"],"URL":"https:\/\/doi.org\/10.1177\/1753466619888127","relation":{},"ISSN":["1753-4666","1753-4666"],"issn-type":[{"value":"1753-4666","type":"print"},{"value":"1753-4666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]},"article-number":"1753466619888127"}}